GASTROENTEROLOGY CLINICS OF NORTH AMERICA北美胃肠病学临床
GASTROENTEROLOGY CLINICS OF NORTH AMERICA(英文缩写 GASTROENTEROL CLIN N),ISSN 0889-8553,eISSN 1558-1942,中文译名:北美胃肠病学临床 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.867 | Q3 |
| 2022 | 3.700 | Q2 |
| 2023 | 2.900 | Q2 |
| 2024 | 3.900 | Q2 |
| 2025 | 3.700 | Q2 |
GASTROENTEROLOGY CLINICS OF NORTH AMERICA 最新收录文献
-
3. Food and Drug Administration-Approved Fecal Microbiota-Based Therapies for Recurrent Clostridioides difficile Infection.
PMID:日期:2026-09-01Recurrent Clostridioides difficile infection remains common despite optimized antibiotic therapy. Two Food and Drug Administration-approved donor-derived fecal microbiota-based products, fecal microbiota, live-jslm (Rebyota / RBL) and fecal microbiota spores, live-brpk (Vowst / VOS) reduce recurrence when administered after completion of standard antibiotics. This review summarizes the clinical development programs supporting these products, including pivotal randomized trials, open-label extensions, durability data, safety outcomes, and emerging real-world evidence. We also discuss patient selection, timing after antibiotics, diagnostic considerations, and practical implementation. These therapies represent standardized, evidence-based approaches to restoring colonization resistance and preventing recurrent infection in appropriately selected adults.
-
4. Non-Fecal Microbiota Transplantation Strategies for Treatment of Recurrent Clostridioides difficile Infection.
PMID:日期:2026-09-01Clostridioides difficile infection (CDI) is a leading healthcare-associated illness with significant recurrence rates and clinical burden. Recurrent CDI (rCDI) arises from microbiota disruption, often exacerbated by antibiotic therapy. Current treatment strategies include fidaxomicin and vancomycin taper regimens, with adjunctive options such as rifaximin in select cases. Preventive approaches focus on environmental decontamination and microbiome preservation. Emerging therapies, including live biotherapeutics, non-toxigenic strains, and microbiome-protective agents, show promise in reducing recurrence. Dietary interventions that enhance microbial diversity may also support recovery. Together, these strategies highlight a shift toward microbiome-centered management of rCDI.
-
5. Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
5. 复发性艰难梭菌感染的粪便微生物群移植PMID:日期:2026-09-01This article synthesizes the evidence supporting fecal microbiota transplantation (FMT) as a paradigm-shifting therapy for recurrent Clostridioides difficile infection (rCDI), highlighting the mechanisms, clinical efficacy across populations, and delivery methods. FMT has been shown to increase gut microbial diversity, restore bile acid metabolism, and induce resistance against colonization, resulting in the treatment of rCDI. Randomized controlled trials and meta-analyses of real-world data demonstrate clinical resolution rates of 85% to 90%, with higher cure rates observed after multiple FMTs. We further examine predictors of FMT failure and outcomes in special populations, underscoring the safety and efficacy of FMT in high-risk patients.
-
6. Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease.
6. 炎症性肠病患者艰难梭菌感染的管理PMID:日期:2026-09-01Clostridioides difficile is a gram-positive, anaerobic bacteria that is ubiquitous. Oral-fecal transmission of the organism and its spores leads to C difficile colonization and infection (CDI) within the human gastrointestinal tract. Patients with inflammatory bowel disease (IBD) are more likely to be colonized with C difficile, develop CDI, and experience recurrence when compared to the general population. The biggest challenge of managing CDI in IBD remains diagnostic uncertainty and relies on clinicians' judgment.
-
7. Treatment of Severe and Fulminant Clostridioides difficile Infections.
7. 严重和暴发性艰难梭菌感染的治疗PMID:日期:2026-09-01Severe and fulminant Clostridioides difficile infection (CDI) represent distinct clinical entities that portend poor outcomes and require close monitoring and multidisciplinary management. Early recognition is key, and CDI-directed antimicrobials are the mainstay of therapy. If patients fail to improve despite maximal medical therapy, fecal microbiota transplantation (FMT) or surgical intervention should be considered. If FMT is performed, repeated dosing is often required. Surgical interventions such as colectomy or loop ileostomy are necessary in FMT nonresponders or those who have developed a complication such as perforation.
-
8. Non-Severe Clostridium difficile Infection.
PMID:日期:2026-09-01Clostridium difficile infection (CDI) is classified as non-severe, severe, or fulminant based on clinical severity and presence of complications. Clinical manifestations span a broad spectrum, ranging from mild self-limited diarrhea to severe colonic inflammation with potentially fatal outcomes. Management strategies for CDI are guided by this severity-based classification. In this article, the authors focus on non-severe CDI, reviewing its definition, diagnostic approach, prevention strategies, treatment options, and predictors of treatment failure. They conclude by highlighting emerging areas of research and future directions in the management of non-severe CDI.
-
9. Probiotics for Primary or Secondary Prevention of Clostridioides difficile Infection.
PMID:日期:2026-09-01Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired infectious diarrhea, often triggered by disruption of the gut microbiota. Recurrence is common after antibiotic treatment, prompting interest in microbial therapies such as probiotics. While some studies suggest probiotics may help prevent initial or recurrent CDI episodes, overall evidence remains inconsistent. Data on prebiotics and synbiotics are even more limited. Although generally safe, probiotics may delay restoration of the normal microbiome, which is key to preventing recurrence. Current guidelines vary from cautious support to discouragement of their use, leaving the role of these therapies in CDI management uncertain and investigational.
-
10. Understanding the Pathophysiology of Clostridioides difficile Infection, Colonization, and Making an Accurate Diagnosis.
PMID:日期:2026-09-01Clostridioides difficile is a gram-positive bacterium and major cause of infectious colitis, in hospital and health care settings, where it remains a significant public health threat. Accurate diagnosis of C difficile infection (CDI) is challenging and requires a clinical assessment supported by laboratory stool testing. Reliance on laboratory tests can lead to both overdiagnosis and underdiagnosis. This article outlines the pathophysiology of C difficile, with emphasis on aspects related to diagnostic testing, and discusses the clinical approach to clinical diagnosis. New therapies for the treatment and prevention of CDI all rely on accurate clinical and laboratory identification of true infection.